[en] Loss of VHR phosphatase causes cell cycle arrest in HeLa carcinoma cells, suggesting that VHR inhibition may be a useful approach to halt the growth of cancer cells. We recently reported that VHR is upregulated in several cervix cancer cell lines as well as in carcinomas of the uterine cervix. Here we report the development of multidentate small-molecule inhibitors of VHR that inhibit its enzymatic activity at nanomolar concentrations and exhibit antiproliferative effects on cervix cancer cells. Chemical library screening was used to identify hit compounds, which were further prioritized in profiling and kinetic experiments. SAR analysis was applied in the search for analogs with improved potency and selectivity, resulting in the discovery of novel inhibitors that are able to interact with both the phosphate-binding pocket and several distinct hydrophobic regions within VHR’s active site. This multidentate binding mode was confirmed by X-ray crystallography. The inhibitors decreased the proliferation of cervix cancer cells, while growth of primary normal keratinocytes was not affected. These compounds may be a starting point to develop drugs for the treatment of cervical cancer.
Research center :
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège
Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew. Chem., Int. Ed. 2005, 44, 3814-3839. (Pubitemid 40885689)
Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7, 833-846.
Ostman, A.; Hellberg, C.; Bohmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6, 307-320.
Tautz, L.; Pellecchia, M.; Mustelin, T. Targeting the PTPome in human disease. Expert Opin. Ther. Targets 2006, 10, 157-177.
Jiang, Z. X.; Zhang, Z. Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev. 2008, 27, 263-272.
Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117, 699-711. (Pubitemid 38748887)
Ishibashi, T.; Bottaro, D. P.; Chan, A.; Miki, T.; Aaronson, S. A. Expression cloning of a human dual-specificity phosphatase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 12170-12174.
Yuvaniyama, J.; Denu, J. M.; Dixon, J. E.; Saper, M. A. Crystal structure of the dual specificity protein phosphatase VHR. Science 1996, 272, 1328-1331. (Pubitemid 26199971)
Alonso, A.; Saxena, M.; Williams, S.; Mustelin, T. Inhibitory role for dual specificity phosphataseVHRin T cell antigen receptor and CD28-induced Erk and Jnk activation. J. Biol. Chem. 2001, 276, 4766-4771.
Todd, J. L.; Rigas, J. D.; Rafty, L. A.; Denu, J. M. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). Oncogene 2002, 21, 2573-2583.
Todd, J. L.; Tanner, K. G.; Denu, J. M. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J. Biol. Chem. 1999, 274, 13271-13280.
Waskiewicz, A. J.; Cooper, J. A. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr. Opin. Cell Biol. 1995, 7, 798-805.
Robinson, M. J.; Cobb, M. H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9, 180-186.
Ip, Y. T.; Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr. Opin. Cell Biol. 1998, 10, 205-219.
Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90, 859-869.
Rahmouni, S.; Cerignoli, F.; Alonso, A.; Tsutji, T.; Henkens, R.; Zhu, C.; Louis-dit-Sully, C.; Moutschen, M.; Jiang, W.; Mustelin, T. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat. Cell Biol. 2006, 8, 524-531.
Woods, D.; Parry, D.; Cherwinski, H.; Bosch, E.; Lees, E.; McMahon, M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21 Cip1. Mol. Cell. Biol. 1997, 17, 5598-5611.
Sewing, A.; Wiseman, B.; Lloyd, A. C.; Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21 Cip1. Mol. Cell. Biol. 1997, 17, 5588-5597.
Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88, 593-602.
Pumiglia, K. M.; Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 448-452.
Wang, W.; Chen, J. X.; Liao, R.; Deng, Q.; Zhou, J. J.; Huang, S.; Sun, P. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol. Cell. Biol. 2002, 22, 3389-3403.
Henkens, R.; Delvenne, P.; Arafa, M.; Moutschen, M.; Zeddou, M.; Tautz, L.; Boniver, J.; Mustelin, T.; Rahmouni, S. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 2008, 8, 147. (Pubitemid 351803799)
Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today 2006, 11, 1046-1053. (Pubitemid 44792477)
Schumacher, M. A.; Todd, J. L.; Rice, A. E.; Tanner, K. G.; Denu, J. M. Structural basis for the recognition of a bisphosphorylated MAP kinase peptide by human VHR protein Phosphatase. Biochemistry 2002, 41, 3009-3017.
Tautz, L.; Mustelin, T. Strategies for developing protein tyrosine phosphatase inhibitors. Methods 2007, 42, 250-260. (Pubitemid 46783589)
Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Muller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 2009, 136, 352-363.
Tautz, L.; Bruckner, S.; Sareth, S.; Alonso, A.; Bogetz, J.; Bottini, N.; Pellecchia, M.; Mustelin, T. Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J. Biol. Chem. 2005, 280, 9400-9408.
Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326. (Pubitemid 27085611)
Collaborative Computational Project, No.4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363.